

The AURORA initiative for metastatic breast cancer

British Journal of Cancer

111, 1881-1887

DOI: [10.1038/bjc.2014.341](https://doi.org/10.1038/bjc.2014.341)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Uncovering the genomic heterogeneity of multifocal breast cancer. <i>Journal of Pathology</i> , 2015, 236, 457-466.	2.1	72
2	What have we learned from exceptional tumour responses?. <i>Current Opinion in Oncology</i> , 2015, 27, 267-275.	1.1	8
3	Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e183-e190.	1.8	19
4	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 541-552.	12.5	121
5	Clinically relevant genetic characterization of prostate tumors: How close are we to the goal?. <i>Korean Journal of Urology</i> , 2015, 56, 90.	1.2	1
6	Biobanking in the era of precision oncology. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 1.	0.1	4
7	The Challenges of Precision Oncology Drug Development and Implementation. <i>Public Health Genomics</i> , 2015, 18, 338-348.	0.6	15
8	Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments. <i>Current Oncology Reports</i> , 2015, 17, 15.	1.8	29
9	Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1253-1267.	1.5	2
10	Precision medicine for metastatic breast cancer—limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 693-704.	12.5	272
11	Clinical management of breast cancer heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 381-394.	12.5	400
12	Precision medicine in oncology drug development: a pharma perspective. <i>Drug Discovery Today</i> , 2015, 20, 1455-1463.	3.2	24
13	Patient-centric trials for therapeutic development in precision oncology. <i>Nature</i> , 2015, 526, 361-370.	18.7	251
14	Translating the Molecular Message of Triple-Negative Breast Cancer into Targeted Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1511-1513.	3.2	6
15	New generation of breast cancer clinical trials implementing molecular profiling. <i>Cancer Biology and Medicine</i> , 2016, 13, 226-235.	1.4	5
16	Conquering Metastatic Breast Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 11-12.	2.5	1
17	Finer Cancer Screens Catch More Cancer Clues. <i>Clinical OMICs</i> , 2016, 3, 8-11.	0.1	0
18	Omics Approaches in Breast Cancer Research and Clinical Practice. <i>Advances in Anatomic Pathology</i> , 2016, 23, 356-367.	2.4	17

#	ARTICLE	IF	CITATIONS
19	Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers. <i>Experimental and Molecular Pathology</i> , 2016, 100, 421-425.	0.9	28
20	Current Status of Clinical Genomics in Patients with Metastatic Breast Cancer. <i>Breast Diseases</i> , 2016, 27, 182-186.	0.0	0
21	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. <i>Oncologist</i> , 2016, 21, 1063-1078.	1.9	41
22	Molecular Testing in Breast Cancer: A Guide to Current Practices. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 815-824.	1.2	43
23	Metastatic breast cancer: The Odyssey of personalization. <i>Molecular Oncology</i> , 2016, 10, 1147-1159.	2.1	19
24	The current use and attitudes towards tumor genome sequencing in breast cancer. <i>Scientific Reports</i> , 2016, 6, 22517.	1.6	22
25	Les essais cliniques : leur apport dans le parcours de soins des patientes traitées pour un cancer du sein. <i>Oncologie</i> , 2016, 18, 103-108.	0.2	1
26	Toward precision medicine of breast cancer. <i>Theoretical Biology and Medical Modelling</i> , 2016, 13, 7.	2.1	48
28	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv362.	3.0	71
29	Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. <i>Oncogene</i> , 2016, 35, 1743-1749.	2.6	13
30	Breast carcinoma subtypes show different patterns of metastatic behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 275-283.	1.4	56
31	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. <i>Medicine (United States)</i> , 2017, 96, e6931.	0.4	3
33	Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. <i>Lancet</i> , 2017, 389, 2430-2442.	6.3	640
34	CDK4/6 blockade in breast cancer: current experience and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1357-1372.	1.9	21
35	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. <i>Oncologist</i> , 2017, 22, 1169-1177.	1.9	14
36	The AURORA pilot study for molecular screening of patients with advanced breast cancer—a study of the breast international group. <i>Npj Breast Cancer</i> , 2017, 3, 23.	2.3	8
37	Intratumoral heterogeneity and subclonal diversification of early breast cancer. <i>Breast</i> , 2017, 34, S36-S42.	0.9	15
38	Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses. <i>Npj Breast Cancer</i> , 2017, 3, 7.	2.3	3

#	ARTICLE	IF	CITATIONS
39	Breast cancer. <i>Lancet</i> , The, 2017, 389, 1134-1150.	6.3	1,568
40	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. <i>International Journal of Molecular Sciences</i> , 2017, 18, 308.	1.8	353
41	Tumor Heterogeneity in Breast Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 227.	1.2	379
42	Quality of Life of Post-Mastectomy Women Living in a Semi-Arid Region of Brazil. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 601.	1.2	7
43	Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. <i>Breast Cancer Research</i> , 2017, 19, 113.	2.2	5
44	Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status. <i>International Journal of Surgery Case Reports</i> , 2018, 53, 102-106.	0.2	4
45	Molecular Biology of Breast Cancer. , 2018, , 569-588.		6
46	Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology. <i>Frontiers in Medicine</i> , 2018, 5, 6.	1.2	14
47	Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 731-740.	1.1	18
48	Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	1
49	Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990â€“2011. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 505-514.	1.1	20
50	Molecular Diagnostics in Breast Cytology. , 2019, , 301-336.		0
51	Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer. <i>Pharmacogenomics Journal</i> , 2019, 19, 15-24.	0.9	5
52	Predictors for hepatocellular carcinoma recurrence after microwave ablation. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 77-84.	0.6	1
53	Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. <i>Breast Cancer Research</i> , 2020, 22, 114.	2.2	25
54	San Huang Decoction Targets Aurora Kinase A to Inhibit Tumor Angiogenesis in Breast Cancer. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542098346.	0.8	2
55	Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 7-22.	0.4	5
56	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 93, 102136.	3.4	25

#	ARTICLE	IF	CITATIONS
57	Curcumin Rescues Doxorubicin Responsiveness via Regulating Aurora a Signaling Network in Breast Cancer Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 957-970.	0.5	9
58	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 676-686.	1.5	20
59	Precision oncology for breast cancer through clinical trials. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 71-78.	1.7	9
60	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
61	Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. <i>Breast Cancer</i> , 2022, 29, 92-102.	1.3	2
62	Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1. <i>Cancer Biology and Therapy</i> , 2021, 22, 465-477.	1.5	6
63	Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. <i>Methods in Molecular Biology</i> , 2016, 1386, 181-219.	0.4	12
64	Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance. <i>PLoS ONE</i> , 2016, 11, e0155840.	1.1	20
65	Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 27953-27965.	0.8	22
66	Tumor Heterogeneity in Breast Cancer. , 2016, , 121-132.		0
68	Mammakarzinom: Intervention in der Axilla – Was ist sinnvoll?. , 0, , .		0
70	Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. <i>Journal of Personalized Medicine</i> , 2021, 11, 1348.	1.1	5
71	Immuno-oncology trends: preclinical models, biomarkers, and clinical development. , 2022, 10, e003231.		20
72	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	1.3	8
73	Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications. <i>Seminars in Cancer Biology</i> , 2022, 86, 769-783.	4.3	36
74	International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01). <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	2